Raras
Buscar doenças, sintomas, genes...
Linfangiomatose kaposiforme
ORPHA:464329CID-10 · D18.1CID-11 · 2E81.10DOENÇA RARA

Anomalia linfática generalizada caracterizada por células endoteliais linfáticas fusiformes kaposiformes.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Anomalia linfática generalizada caracterizada por células endoteliais linfáticas fusiformes kaposiformes.

Pesquisas ativas
2 ensaios
4 total registrados no ClinicalTrials.gov
Publicações científicas
88 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D18.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
7 sintomas
🦴
Ossos e articulações
5 sintomas
🫁
Pulmão
4 sintomas
🫃
Digestivo
3 sintomas
🫘
Rins
2 sintomas
👁️
Olhos
1 sintomas

+ 23 sintomas em outras categorias

Características mais comuns

90%prev.
Derrame pleural
Muito frequente (99-80%)
90%prev.
Anormalidade do sistema linfático
Muito frequente (99-80%)
90%prev.
Morfologia pulmonar anormal
Muito frequente (99-80%)
90%prev.
Morfologia anormal do mediastino
Muito frequente (99-80%)
90%prev.
Morfologia anormal do vaso linfático
Muito frequente (99-80%)
55%prev.
Anormalidade do sistema respiratório
Frequente (79-30%)
46sintomas
Muito frequente (5)
Frequente (10)
Ocasional (26)
Muito raro (5)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 46 características clínicas mais associadas, ordenadas por frequência.

Derrame pleuralPleural effusion
Muito frequente (99-80%)90%
Anormalidade do sistema linfáticoAbnormality of the lymphatic system
Muito frequente (99-80%)90%
Morfologia pulmonar anormalAbnormal lung morphology
Muito frequente (99-80%)90%
Morfologia anormal do mediastinoAbnormality of the mediastinum
Muito frequente (99-80%)90%
Morfologia anormal do vaso linfáticoAbnormal lymphatic vessel morphology
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico88PubMed
Últimos 10 anos83publicações
Pico202515 papers
Linha do tempo
2026Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Linfangiomatose kaposiforme

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

4 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
84 papers (10 anos)
#1

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

Pediatric blood &amp; cancer2026 Mar

An activating NRAS p.Q61R (NRASQ61R) somatic mutation occurs in the lesions of patients with kaposiform lymphangiomatosis (KLA). Therapies for KLA patients are limited and since the mitogen-activated protein kinase pathway is hyperactivated by NRASQ61R, we evaluated the potency of Mitogen-activated protein kinase kinase (MEK) inhibitors (trametinib, selumetinib, and cobimetinib) on human NRASQ61R endothelial cells (ECs). RNA sequencing analysis was performed to identify dysregulated genes and those restored by trametinib. Trametinib was tested in a mouse xenograft model of NRASQ61R ECs. Doxycycline (Dox)-inducible NRASQ61R ECs were treated with trametinib, selumetinib, cobimetinib, or vehicle (control). Cell signaling pathways, proliferation, migration, morphology, and angiopoietin-2 (ANG-2) levels were assessed. RNA-sequencing analysis was performed on Dox-induced NRAS wild-type (NRASWT), NRASQ61R, and trametinib-treated NRASQ61R ECs. Selected proteins were verified by immunoblotting. NRASQ61R ECs were injected into nude mice on Dox-containing diet to generate xenografts and treated with trametinib or vehicle. Trametinib reduced NRASQ61R-activated ERK phosphorylation, cell proliferation, migration, spindling, and ANG-2 at lower doses than selumetinib or cobimetinib. RNA-sequencing detected 1315 upregulated and 1773 downregulated genes in NRASQ61R ECs compared with NRASWT. Trametinib corrected 19% upregulated and 8% downregulated genes, including elevated Notch ligands (DLL4, JAG1), activated Notch 1, and HES1. Trametinib reduced NRASQ61R ECs xenograft weights by 46%, vascular area by 63%, and phosphorylated ERK staining. Trametinib was the most effective MEK inhibitor, correcting some dysregulated genes in NRASQ61R ECs, including some in the Notch pathway. Trametinib reduced vessel overgrowth in xenografts of NRASQ61R ECs. These studies support using trametinib treatment for KLA patients with an NRASQ61R mutation.

#2

Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.

Pediatric blood &amp; cancer2026 Jan

This study evaluated trametinib in five pediatric patients (median age 9 years) with complex lymphatic malformations, such as kaposiform lymphangiomatosis (KLA) and generalized lymphatic anomaly (GLA). All showed significant clinical improvement: coagulopathy resolved (platelet increase 54%-362%, D-dimer decrease > 91%), 80% achieved partial response radiographically, and toxicity was minimal (one Grade 2 rash). NRAS proto-oncogene mutations were detected in 80% of cases, but clinical benefit occurred without mutation. Trametinib is an effective, safe, first-line therapy for KLA/GLA.

#3

Pregnancy Complicated by 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency and Kaposiform Lymphangiomatosis.

O&amp;G open2026 Feb

To describe pregnancy complicated by deficiency of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase, an inborn error of metabolism, and kaposiform lymphangiomatosis (KLA), a lymphatic anomaly with poor prognosis. A 24-year-old woman with known HMG-CoA lyase deficiency and KLA presented at 6 weeks of gestation with severe vomiting and dehydration. Her pregnancy was complicated by worsening lung disease, fetal growth restriction, anemia, thrombocytopenia, and gestational diabetes. She required parenteral nutrition and adjustments in immunosuppressive therapy. At 37 weeks, she underwent induction of labor and delivered a male infant weighing 2,790 g with reassuring Apgar scores. This case demonstrates that, with multidisciplinary management, patients with coexisting rare disorders can achieve successful pregnancy outcomes despite substantial maternal and fetal risks.

#4

Case Report: Life-threatening Kasabach-Merritt phenomenon in a 2-month-old child.

Frontiers in pediatrics2025

We present a rare case of a 2-month-old girl, born at term, who was admitted to the pediatric intensive care unit for fussiness, increasing abdominal distension, and intermittent diarrhea for one week. She was found to be hypertensive, coagulopathic, and suffering from unrelenting ascites. Over the course of the following month, her symptoms became life-threatening, and she was intubated, sedated, and paralyzed. She underwent multiple diagnostic and therapeutic procedures, including exploratory laparotomy, MRI, colonoscopy, and multiple peritoneal drains. After several weeks, the medical teams reached a consensus diagnosis of a rare and complex vascular anomaly characterized by a life-threatening Kasabach-Merritt Phenomenon (KMP). KMP is known to occur in association with several anomalies, including kaposiform hemangioendothelioma and kaposiform lymphangiomatosis. Life-saving therapies were initiated, including methylprednisolone and sirolimus. The patient was ultimately discharged and sent home with her parents. To our knowledge, this is the only reported case describing this constellation of symptoms in a critically ill infant. Multidisciplinary cooperation was key in saving the patient's life. Critical care providers should consider vascular anomalies in patients with similar presentations.

#5

Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform Lymphangiomatosis.

Pediatric blood &amp; cancer2025 Nov

Kaposiform lymphangiomatosis (KLA) is a complex lymphatic anomaly characterized by lymphatic overgrowth and dysfunction. The goal of this study was to determine how the NRASQ61R variant found in the tissue of KLA patients impacts key characteristics of lymphatic endothelial cells (LEC). LEC expressing NRASQ61R had a spindled morphology, increased migration, increased proliferation, increased MAPK signaling, and elevated angiopoietin-2 production. In an in vitro lymphangiogenesis model, LEC expressing NRASQ61R showed increased sprouting and formed enlarged and disorganized vascular structures. This model of LEC expressing NRASQ61R can be used to give insights into KLA pathogenesis and test new treatments.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC55 artigos no totalmostrando 81

2025

Trametinib normalizes angiopoietin-2 levels and successfully treats kaposiform lymphangiomatosis.

Journal of vascular anomalies
2026

Pregnancy Complicated by 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency and Kaposiform Lymphangiomatosis.

O&amp;G open
2026

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

Pediatric blood &amp; cancer
2025

Complex Lymphatic Anomalies: A Comprehensive Review of Imaging Features and Diagnostic Considerations.

Seminars in roentgenology
2025

Case 343: Kaposiform Lymphangiomatosis.

Radiology
2025

Case Report: Life-threatening Kasabach-Merritt phenomenon in a 2-month-old child.

Frontiers in pediatrics
2026

Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.

Pediatric blood &amp; cancer
2025

Case Report: 3 cases of abdominal lesions with lower limb lymphedema-rare mutations in complex lymphatic anomalies.

Frontiers in oncology
2025

Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform Lymphangiomatosis.

Pediatric blood &amp; cancer
2025

A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA).

The Journal of experimental medicine
2025

Lymphatic Malformation: Classification, Pathogenesis, and Therapeutic Strategies.

Annals of vascular surgery
2025

Lymphatic malformations involving the thorax in children: a retrospective cohort study.

BMC pulmonary medicine
2025

Perioperative Considerations for a Patient with Juvenile Idiopathic Scoliosis and Kaposiform Lymphangiomatosis Undergoing Spinal Fusion: A Case Report.

Journal of orthopaedic case reports
2025

Complex lymphatic anomalies.

Pediatric radiology
2025

Primary splenic involvement in kaposiform lymphangiomatosis: A case report.

International journal of surgery case reports
2025

Life-threatening Lymphatic Malformation With Somatic Activating NRAS Mutation Successfully Treated With Trametinib: A Case Study.

Journal of pediatric hematology/oncology
2025

Lyve1-Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic Mice.

Pediatric blood &amp; cancer
2025

Advances in vascular anomalies: refining classification in the molecular era.

Histopathology
2024

Kaposiform Lymphangiomatosis as a Cause of Vaginal Bleeding & Discharge: A Case Report.

Journal of pediatric and adolescent gynecology
2024

Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib.

Pediatric dermatology
2024

Changes in cell morphology and function induced by the NRAS Q61R mutation in lymphatic endothelial cells.

PloS one
2024

Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies.

Pediatric blood &amp; cancer
2024

Lymphatic endothelial cell-specific NRAS p.Q61R mutant embryos show abnormal lymphatic vessel morphogenesis.

Human molecular genetics
2024

NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model.

Pediatric blood &amp; cancer
2024

How we use angiopoietin-2 in the diagnosis and management of vascular anomalies.

Pediatric blood &amp; cancer
2024

Differential Diagnosis of Generalized Cystic Lymphangiomatosis: A Literature Review.

Current medical imaging
2024

Regression of kaposiform lymphangiomatosis and chronic disseminated intravascular coagulation after inhaled budesonide-formoterol treatment.

Pediatric blood &amp; cancer
2024

Challenging diagnosis of Kaposiform lymphangiomatosis: Unveiling a rare primary lymphatic disorder.

Radiology case reports
2023

Refractory kaposiform lymphangiomatosis relieved by splenectomy.

Frontiers in pediatrics
2023

Insights Image for "Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition".

Pediatric research
2023

Pathogenic variants in PIK3CA are associated with clinical phenotypes of kaposiform lymphangiomatosis, generalized lymphatic anomaly, and central conducting lymphatic anomaly.

Pediatric blood &amp; cancer
2023

Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics.

Journal of investigative medicine high impact case reports
2023

The novel use of an advanced thrombectomy system to manage a complex pericardial effusion associated with kaposiform lymphangiomatosis.

Cardiology in the young
2023

Splenic Lesions and Other Findings in Kaposiform Lymphangiomatosis.

The American journal of surgical pathology
2023

Complex Lymphatic Anomalies: Report on a Patient Registry Using the Latest Diagnostic Guidelines.

Lymphatic research and biology
2023

Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.

Pediatric blood &amp; cancer
2022

[Kaposiform lymphangiomatosis diagnosed by circulating tumor DNA in a child].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2022

Recurrent haemoptysis: a rare diagnosis of kaposiform lymphangiomatosis and review of literature.

BMJ case reports
2022

Kaposiform lymphangiomatosis complicated with effusive constrictive pericarditis: a rare systemic malformation involving the heart.

European heart journal. Cardiovascular Imaging
2022

NRASQ61R mutation in human endothelial cells causes vascular malformations.

Angiogenesis
2022

Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.

The American journal of surgical pathology
2023

Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

Pediatric research
2022

Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion.

BMJ case reports
2022

Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.

Human pathology
2021

CT and MRI Findings of Focal Splenic Lesions and Ascites in Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.

Journal of clinical imaging science
2022

Multidisciplinary Multiagent Treatment of Complex Lymphatic Anomalies with Severe Bone Disease: A Single-Site Experience.

Lymphatic research and biology
2021

Cerebrospinal fluid-lymphatic fistula causing spontaneous intracranial hypotension in a child with kaposiform lymphangiomatosis.

Pediatric radiology
2021

Sirolimus in the treatment of kaposiform lymphangiomatosis.

Orphanet journal of rare diseases
2021

Characterization of kaposiform lymphangiomatosis tissue-derived cells.

Pediatric blood &amp; cancer
2022

How we approach the diagnosis and management of complex lymphatic anomalies.

Pediatric blood &amp; cancer
2021

Isolated abdominal kaposiform lymphangiomatosis: a novel presentation of a rare entity.

Pathology
2020

Kaposiform lymphangiomatosis effectively treated with MEK inhibition.

EMBO molecular medicine
2020

Thoracic duct embolization in kaposiform lymphangiomatosis.

Journal of vascular surgery. Venous and lymphatic disorders
2020

Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels.

Pediatric blood &amp; cancer
2020

Analysis of mTOR pathway expression in lymphatic malformation and related diseases.

Pathology international
2020

Bone development and fracture healing is normal in mice that have a defect in the development of the lymphatic system.

Lymphology
2019

[Clinical characteristics of Kaposiform lymphangiomatosis: a report of 8 cases].

Zhonghua wai ke za zhi [Chinese journal of surgery]
2020

Kaposiform lymphangiomatosis with spinal involvement.

QJM : monthly journal of the Association of Physicians
2020

Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.

Pediatric blood &amp; cancer
2019

Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

Orphanet journal of rare diseases
2019

Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

Orphanet journal of rare diseases
2019

Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights.

Advances in wound care
2019

Potential biomarkers of kaposiform lymphangiomatosis.

Pediatric blood &amp; cancer
2019

The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.

Orphanet journal of rare diseases
2019

Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Pediatric blood &amp; cancer
2019

Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.

Hematology/oncology clinics of North America
2019

[Our experience with sirolimus for the treatment of complicated vascular anomalies].

Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica
2019

A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

Genetics in medicine : official journal of the American College of Medical Genetics
2018

Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell-like Pericytes Defective in Vessel Formation.

Journal of pediatric hematology/oncology
2018

Chest imaging in generalized lymphatic anomaly and kaposiform lymphangiomatosis.

Pediatrics international : official journal of the Japan Pediatric Society
2018

Pseudotumor cerebri in kaposiform lymphangiomatosis: a case report and pathogenetic hypothesis.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2017

MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis.

Japanese journal of radiology
2018

Vascular anomaly cases for the pediatric hematologist oncologists-An interdisciplinary review.

Pediatric blood &amp; cancer
2017

Kaposiform Lymphangiomatosis with Human Papillomavirus Infection.

American journal of respiratory and critical care medicine
2017

Angiopoietins as serum biomarkers for lymphatic anomalies.

Angiogenesis
2016

Point-of-Care Thoracic Ultrasonography in the Diagnosis and Management of Kaposiform Lymphangiomatosis.

Pediatric emergency care
2017

Sirolimus in the Treatment of Vascular Anomalies.

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
2016

Nonmalignant Adult Thoracic Lymphatic Disorders.

Clinics in chest medicine
2016

Imaging features of kaposiform lymphangiomatosis.

Pediatric radiology
2016

Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.

Pediatric blood &amp; cancer
2015

Successful treatment of kaposiform lymphangiomatosis with sirolimus.

Pediatric blood &amp; cancer

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Linfangiomatose kaposiforme.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Linfangiomatose kaposiforme

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.
    Pediatric blood &amp; cancer· 2026· PMID 41496696mais citado
  2. Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.
    Pediatric blood &amp; cancer· 2026· PMID 41116710mais citado
  3. Pregnancy Complicated by 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency and Kaposiform Lymphangiomatosis.
    O&amp;G open· 2026· PMID 41625680mais citado
  4. Case Report: Life-threatening Kasabach-Merritt phenomenon in a 2-month-old child.
    Frontiers in pediatrics· 2025· PMID 41244261mais citado
  5. Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform Lymphangiomatosis.
    Pediatric blood &amp; cancer· 2025· PMID 40879319mais citado
  6. NRAS(Q61R) Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis.
    Pediatr Blood Cancer· 2026· PMID 41992710recente
  7. Trametinib normalizes angiopoietin-2 levels and successfully treats kaposiform lymphangiomatosis.
    J Vasc Anom (Phila)· 2025· PMID 41788185recente
  8. Complex Lymphatic Anomalies: A Comprehensive Review of Imaging Features and Diagnostic Considerations.
    Semin Roentgenol· 2025· PMID 41349185recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:464329(Orphanet)
  2. MONDO:0018736(MONDO)
  3. GARD:13451(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q55788298(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Linfangiomatose kaposiforme
Compêndio · Raras BR

Linfangiomatose kaposiforme

ORPHA:464329 · MONDO:0018736
Prevalência
Unknown
Herança
Not applicable
CID-10
D18.1 · Linfangioma de qualquer localização
CID-11
Ensaios
2 ativos
Início
Childhood
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C5681097
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades